Brand name: Delstrigo TM
Active ingredients: doravirine + lamivudine + tenofovir disoproxil
What it is used for
DELSTRIGO is indicated for the treatment of HIV-1 infection in adult patients: With no prior antiretroviral history, OR To replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to doravirine, lamivudine, or tenofovir.
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 30 degrees Celsius
- Store in Original Container
- Keep Container Tightly Closed/Airtight
- Shelf lifetime is 12 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Yellow, oval-shaped, film-coated tablet, debossed with the corporate logo and 776 on one side and plain on the other side.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
